Everest Medicines Announces 2025 Interim Results: ‘Dual-Engine’ Strategy Driving Strong Synergies Between Commercialization and R&D
HONG KONG, Sep 1, 2025 – (ACN Newswire via SeaPRwire.com) – On August 29, Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The […]